

Rejuvant[®], a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test

Oleksandr Demidenko^{1,*}, Diogo Barardo^{2,*}, Valery Budovskii¹, Robb Finnemore³, Francis R. Palmer III³, Brian K. Kennedy^{2,3,4,5}, Yelena V. Budovskaya¹

¹TruMe Inc., Alameda, CA 94502, USA

²Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University Singapore, Singapore 117456, Singapore

³Ponce de Leon Health, Fernandina, FL 32034, USA

⁴Centre for Healthy Longevity, National University Health System, Singapore 117456, Singapore

⁵Singapore Institute for Clinical Sciences, A*STAR, Singapore 117609, Singapore

*Equal contribution

Correspondence to: Brian K. Kennedy, Yelena V. Budovskaya; **email:** bkennedy@nus.edu.sg, yelena@trumelabs.com

Keywords: aging, DNA methylation, alpha-ketoglutarate (AKG), biologic age, Rejuvant

Received: October 5, 2021

Accepted: November 15, 2021

Published: November 30, 2021

Copyright: © 2021 Demidenko et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The search continues for possible interventions that delay and/or reverse biological aging, resulting in extended healthspan and lifespan. Interventions delaying aging in animal models are well established; however, most lack validation in humans. The length of human lifespan makes it impractical to perform survival analysis. Instead, aging biomarkers, such as DNA methylation (DNAm) clocks, have been developed to monitor biological age. Herein we report a retrospective analysis of DNA methylation age in 42 individuals taking Rejuvant[®], an alpha-ketoglutarate based formulation, for an average period of 7 months. DNAm testing was performed at baseline and by the end of treatment with Rejuvant[®] supplementation. Remarkably, individuals showed an average decrease in biological aging of 8 years ($p\text{-value}=6.538\times 10^{-12}$). Furthermore, the supplementation with Rejuvant[®] is robust to individual differences, as indicated by the fact that a large majority of participants decreased their biological age. Moreover, we found that Rejuvant[®] is of additional benefit to chronologically and biologically older individuals. While continued testing, particularly in a placebo-controlled design, is required, the nearly 8-year reversal in the biological age of individuals taking Rejuvant[®] for 4 to 10 months is noteworthy, making the natural product cocktail an intriguing candidate to affect human aging.

INTRODUCTION

Aging is a near universal biological process that manifests as a general decline in health and vitality, eventually leading to death. Aging is associated with the development of a wide range of chronic diseases, including cancer, Alzheimer's, diabetes, cardiovascular disease and many other conditions [1, 2]. If aging can be

delayed, chronic disease onset will be forestalled, functional capacity maintained and, in all likelihood, complications due to infectious diseases, such as Covid-19 and influenza, reduced [3]. In short, humans will have a longer healthspan and lifespan.

Aging is typically measured chronologically in days or years, with median human survival on the order of

eight decades. If we hope to control the aging process, we need to learn how to measure the rate of aging in shorter time periods. Moreover, aging progresses at different rates in different individuals. Our true biological age is influenced by many additional factors, such as genetic background, lifestyle, and disease. To address this challenge, several biological markers of aging have been developed. These markers are unique sets of molecules or changes in the epigenetic state of an individual's DNA that reflect their current aging status [4–6]. Among the most promising biomarkers of the aging process are DNA methylation patterns. DNA methylation is an epigenetic mechanism that plays an important role in the regulation of gene expression, organism development and disease [7, 8].

Methylation of lysine residues within core histones, H3 and H4, initiates a conformational modification in the chromatin structure that is associated with changes in transcriptional activity. However, the most widely studied epigenetic mark is the direct methylation of DNA itself. This modification involves the conversion of cytosine to 5'-methylcytosine, catalyzed by DNA methyltransferases, and typically occurs within the CpG dinucleotide sequences (CpGs). These CpG sequences, clustered in regions known as CpG islands (CGIs), are most often found in promoters of housekeeping genes [9, 10]. It has been shown that hypermethylation of CpG islands is linked with transcriptional silencing, whereas demethylated CpG islands are more often found during embryogenesis and serve as a hallmark of actively transcribed genes. During aging, two types of changes in DNA methylation have been observed and carefully characterized: (1) epigenetic drift, or progressive stochastic changes in DNA methylation patterns between individuals that occurs with increasing age [11], and (2) the epigenetic clock – a DNA methylation-derived measure that is highly correlated with chronological age and proposed to measure biological age [9, 12, 13].

The epigenetic clock is an attractive biomarker of aging because it applies to most human tissues, capturing aspects of biological age such as frailty [14], cognitive/physical fitness in the elderly [15], age-acceleration in obesity [16], premature aging in Down's syndrome [17] and HIV infection [18], Parkinson's [19] and Alzheimer's disease-related neuropathologies [20], as well as cancer [21] and lifetime stress [22]. Markers of biological aging represent an important tool to clinically validate the effects of longevity-based interventions. For the first time, these biomarkers of aging give scientists the opportunity to study the effects of anti-aging compounds in real-time and directly in humans. One of the most promising anti-aging

compounds discovered to date is Alpha-Ketoglutarate (AKG) [23].

AKG is an endogenous intermediary metabolite in the Krebs cycle whose levels naturally decline during aging. AKG is involved in multiple metabolic and cellular pathways. These include functioning as a (an) signaling molecule, energy donor, precursor in the amino acid biosynthesis, and a regulator of epigenetic processes and cellular signaling via protein binding [24–26]. AKG deficiency in stem and progenitor cells increases with age [27]. As animals age, mitochondrial function is progressively impaired and cellular metabolic flux in the mitochondria declines, which exacerbates AKG deficiency. Chin et al. reported that AKG increased the lifespan of *C. elegans* [28]. Building on these results, AKG (and calcium salt) combined with other Generally Recognized as Safe (GRAS) compounds were studied in mice. The non-genetically altered mouse is the preferred mammalian model to study aging, since the biochemical processes involved in mice aging may apply to other mammals, including humans [29]. In a recent study, sponsored by Ponce de Leon Health and performed at the Buck Institute for Research on Aging, the effect of alpha-ketoglutarate (delivered in the form of a calcium salt - CaAKG) on healthspan and lifespan in C57BL/6 mice was reported. The authors showed that in the mice, AKG reduced frailty and enhanced longevity, indicating a compression of morbidity [23]. These and other discoveries suggest that AKG may be an ideal candidate for pro-longevity human studies.

In this study, we examined the cross-sectional and longitudinal association between the epigenetic clock, health status, physical fitness and the effects of taking Rejuvant® (sustained release CaAKG + a specific vitamin depending on sex) on human biological aging. We followed 42 self-reported healthy individuals who had taken AKG supplementation for a period of 4 to 10 months. The effects of AKG on biological aging, and the possible correlation of other physiological effects, are discussed.

RESULTS

For this study, we reviewed 42 participants who had elected to take Rejuvant® for a period of 4 to 10 months. All participants were actively on the Rejuvant® product. The need to follow this study with a placebo-controlled study is described in the Discussion. The general characteristics of this cohort are described in Table 1. All participants reported good or excellent health status without any chronic medical conditions. Only one participant was a smoker at baseline and

Table 1. Descriptive characteristics of the study participants.

Total Participants	42
Gender (Female/ Male)	14/ 28
Female:	
Chronological Age (median; range)	64.09; 43.49 to 72.46
Biological Age at Baseline (median; range)	62.15; 46.4 to 73
Biological Age at T7* (median; range)	55.55; 33.4 to 63.7
Male:	
Chronological Age (median; range)	62.78; 41.31 to 79.57
Biological Age at Baseline (median; range)	61.85; 41.9 to 79.7
Biological Age at T7* (median; range)	53.3; 33 to 74.9

*Indicates biological age as measured by TruMe test after an average of seven months of treatment.

continued to smoke throughout the study. The majority of the study participants (66.7%, n = 28) were male. The mean chronological age of this cohort was approximately 63 years old.

For all 42 participants, we were able to measure the baseline biological age using the TruMe age prediction model before they began taking Rejuvant®. We utilized the TruAge prediction model with Sanger sequencing for DNA methylation analysis. In total, 3 genes including 9 CpG sites were analyzed by the Sanger sequencing. The DNA methylation values obtained for all CpG sites were included in the TruMe age-prediction model (pending publication).

We assessed the prediction error of the TruAge epigenetic test, as previously described. Comparison of the predicted vs. actual age values yields a median absolute error of 4.23 years. The mean error of 0.35 years shows that this population as a whole may be slightly younger than expected. It is known that pre-processing normalization of DNA methylation datasets and their age variance can bias the difference between the estimated and chronological age. A measure of robustness to these factors involves calculating the residuals of a linear regression of predicted vs. actual age. We found the estimated age to have a regression coefficient of 0.88 and that the linear regression (line fitted in Figure 1) displayed an adjusted R-squared of 0.59 with a median absolute error of 3.97 years. Finally, we also found a statistically significant (p-value=2.026x10⁻⁹) Pearson linear correlation of 0.77 (95% CI: 0.61 to 0.87) between our cohort's estimated and actual age at baseline.

We also considered whether there was a sex bias of the biological age assessment by analyzing males (28) and females (14) separately. Following the same procedure as before, for males we found a median absolute error of

the predicted vs actual age of 4.92 years, and a mean error of -0.22 years. The median absolute error of the linear regression was 4.64 years, with an adjusted R-squared of 0.6 and a regression coefficient of 0.90 (Figure 2). Additionally, estimated and actual age at baseline for males were linearly correlated (p-value=7.74x10⁻⁷) with a magnitude of 0.78 (95% CI: 0.58 to 0.9). For females the analogous regression procedure displayed a median absolute error of 3.887 years, with an adjusted R-square of 0.51 and a regression coefficient of 0.83 (Figure 2). Furthermore, we found a median absolute error of the predicted vs actual age of 3.41 years. The mean error of 1.48 years could indicate that the females of our cohort are likely to be younger than expected. To explore this, we applied a multilinear regression with gender as an additional variable to our entire cohort. Gender was not found to be a statistically significant predictor of chronological age at baseline (Table 2). Moreover, there was a statistically significant (p-value=0.002) linear correlation of 0.74 (95% CI: 0.35 to 0.91) between the estimated and real age at baseline for females. In conclusion, within the context of this limited dataset, there was no statistical difference in the predictive ability of the TruAge epigenetic test with respect to males and females.

Participants completed a survey at the start and end of the trial. This self-reported questionnaire included information about diet, alcohol intake, previous consumption of Rejuvant®, health, height and weight (which allowed for estimation of BMI), sleep duration, smoking status, exercise frequency, physical activity level, meal frequency, snacking frequency, number of additional dietary supplements consumed and frequency, hair status, education, healthy lifestyle mindset and trust in dietary supplements (Supplementary Table 1).

We leveraged baseline survey information to check if there were other confounders in our cohort, performing




Figure 1. TruAge age estimation and baseline chronological age are linearly correlated. The TruAge biological age is highly (adjusted R-squared = 0.77) statistically significantly (p -value = 2×10^{-9}) correlated with chronological age of the 42 patients.




Figure 2. TruAge age estimation and baseline chronological age are linearly correlated, in both genders. The x-axis depicts DNA methylation age estimated by TruAge, and the y-axis the chronological age of the 42 patients at baseline. The pink and blue linear correlation plots depict the similarly high statistically significant linear correlation between both axes, for female and male patients, respectively.

Table 2. Effect of Rejuvant® on biological age of study participants.

Biological age distributions	Male participants (in years)	Female participants (in years)
Minimum Biological Age at Baseline	41.9	46.4
Median Biological Age at Baseline	61.85	62.15
Mean Biological Age at Baseline	61.38	61.09
Maximum Biological Age at Baseline	79.7	73
Minimum Biological Age at T7*	33	33.4
Median Biological Age at T7*	53.3	55.55
Mean Biological Age at T7*	53.53	54.66
Maximum Biological Age at T7*	74.9	63.7
Minimum change in Biological Age	-1.86	-0.41
Median change in Biological Age	7.09	5.83
Mean change in Biological Age	8.44	6.98
Maximum change in Biological Age	22.7	14.09

*Indicates biological age as measured by TruMe test after an average of seven months of treatment.

a multivariable linear regression. Due to the considerable number of predicative variables, we performed a stepwise linear regression. Although there were additional covariates selected in the stepwise model, when this was compared, by means of analysis of variance, with the simpler univariate linear regression using solely the TruAge estimated age, the obtained p-value was 0.12 (Supplementary Table 2). This indicates that in terms of comparison, the two models are not statistically significantly different, and, therefore, the simpler model was selected.

It was of interest to determine whether the difference between chronological age and TruAge is related to lifestyle or demographic factors. In other words, it is important to assess if these covariates are associated with biologically younger or older individuals. We selected BMI, alcohol consumption, self-assessed health, sleep duration, smoking history, exercise frequency and intensity, and hair abundance as predictor variables, since this subset of the survey information collected may clearly be associated with and/or influence biological age. The stepwise linear regression did not find any statistically significant association between any of these variables with the difference between chronological and TruAge biological age (Supplementary Table 2). Of note, the number of participants is quite small (for instance, there was one smoker, and only 6 who reported a history of smoking). Therefore, it is likely that one or more of these lifestyle parameters influence the biological age as measured by the TruAge test and that a larger dataset would uncover associations.

Results of the CaAKG consumption on biological age

The goal of the study was to determine the effect of Rejuvant® supplementation on human biological aging

by measuring DNA methylation. Following the baseline measurement, each study participant was supplied Rejuvant® for the duration of the study. Even though the participants were advised to use the treatment for 4 to 6 months, there was considerably individual differences in treatment duration. Upon completion of the self-chosen treatment period, participants submitted their saliva samples for analysis of their biological age using commercially available TruMe tests.

Based on the questionnaires submitted at baseline and the end of the trial, we identified a subset of 13 individuals who reported no changes in diet type, drinking frequency, additional dietary supplements intake, sleep duration and exercise frequency. This homogeneous subset was therefore used for the preliminary assessment of the independent effect of CaAKG, as the other covariates are controlled for by design.

At baseline, this subset or our cohort was on average 2.06 years biologically younger than their chronological age. By the end of the treatment this sub-population was on average 9.74 years biologically younger than their respective chronological age. Using one-sided Welch two sample paired t-test, this difference in means of 7.69 years was found to be statistically significant, with a p-value of 7.263×10^{-5} (Figure 3). It is noteworthy that every subject in this small group decreased their biological age.

After discovering that CaAKG supplementation consistently decreased epigenetic age in a small homogenous population, we continued by assessing its effects on the entire cohort of 42 patients. At baseline, the cohort was on average 0.35 years biologically younger than their chronological age. By the end of the treatment, this value changed to an average of 8.31 years biologically younger than their respective

chronological age. Using one-sided Welch two sample paired t-test, this difference in means of 7.96 years was found to be statistically significant, with a p-value of 6.538×10^{-12} (Figure 4).

The formulation of the Rejuvant® supplement is itself different for males and females. More specifically, in addition to CaAKG, vitamin A and vitamin D are added

to the men's or women's commercial formulation, respectively (see Methods). Regardless, the effect of supplementation with Rejuvant® decreases epigenetic age in a statistically significant manner in males and females (Figure 5). The paired mean decrease is 8.44 years in males and 6.98 years in females. Only 2 individuals (1 male and 1 female) exhibited a slightly increase in biological age.




Figure 3. CaAKG decreased methylation age among a homogeneous sub-population. The paired box plots represent the treatment effects at the patient and group level (n=13), between baseline and end of the trial (which on average had a duration of 7 months). The box plots depict the median and the 25th and 75th quartiles.

The validity of the statistical analysis using the entire cohort is predicated on covariate modelling, for the detection of variables that result in a statistically significant difference in the TruMe DNA methylation test, we used stepwise regressions iteratively. This procedure culminated in the most parsimonious model using only baseline chronological age, and the difference between

baseline chronological and biological ages, as the only statistically significant predictors of the magnitude of the decrease in epigenetic age by Rejuvant®. Accordingly, we modelled the effect of Rejuvant® supplementation on methylation age as a linear regression of these two variables. These data indicate that those people with higher biological age (relative to their chronological age)




Figure 4. CaAKG decreased methylation age in the entire cohort. The paired box plots represent the treatment effects at the patient and group level (n=42), between baseline and end of the trial (which on average had a duration of 7 months). The box plots depict the median and the 25th and 75th quartiles.

and/or people with high baseline chronological age have the largest response to Rejuvant®.

Using the final reduced model, with only the two variables found to be statistically significantly related with a decrease in epigenetic age over the course of the treatment, the epigenetic age difference (in years) of about 7 months of CaAKG supplementation can be modeled by the equation:

$$\text{Decrease in TruAge} = -5.41 + 0.22 \times \text{age} - 0.45 \times \text{diffAge}$$

with “age” standing for chronological age at the start of the treatment and “diffAge” defined as the difference between chronological age and TruMe age at baseline. The plane representing this regression is depicted (Figure 6).

Interestingly, duration of the treatment is not correlated with the magnitude of the effect of Rejuvant® supplementation. This indicates that the median treatment duration of our cohort, approximately 7 months, may be sufficient to saturate the benefits of the supplementation.




Figure 5. CaAKG decreases methylation age regardless of gender. The image displays the effects of CaAKG on methylation age between the start and end of treatment, broken down by gender. For each gender, the red and blue paired box plots, depict the data at baseline and endpoint, respectively. The boxplots are based on the median and the 25th and 75th quartiles.

Interestingly, this finding is consistent with mathematical extrapolations from a large-scale study of complete blood count measurements, which forecast that the effects of a longevity intervention in a healthy population will saturate in a short period of time [30]. This same study predicted that the benefits of such interventions would be greater in individuals closer to a frail state, consistent with our data.

Having said this, there remains very little data on longer term use of Rejuvant® or higher doses of the product, and further effects on biological age are feasible. We also did not measure whether the benefits in biological age are lost if the supplement is discontinued, therefore, continual supplementation may be needed to maintain any effects observed.




Figure 6. 3D scatter plot of the covariates influencing CaAKG treatment efficacy. The x-axis refers to the difference, in years, between the chronological and biological ages at baseline (a patient in an older state will have larger positive value). The y-axis depicts the effect of CaAKG treatment in terms of years that the methylation age decreased (higher values indicate larger benefits). The z-axis is the chronological age at baseline (older patients will be “deeper”). The 3D plane was traced by using the linear regression of both covariates to treatment effect.

DISCUSSION

AKG has been shown to extend lifespan in various model systems. In this study, we used a previously developed algorithm that predicts human biological age to determine if Rejuvant®, sustained release CaAKG + vitamins has a beneficial effect on human longevity. A total of 42 individuals, known to be taking Rejuvant® and who had submitted saliva samples for DNA methylation testing, were selected to participate in a customer biological aging result survey and analysis. Their DNAm TruAge Index had been measured at baseline (before starting Rejuvant®) and retested after an average of 7 months of use. Overall, these 42 individuals showed statistically significant average reduction in their biological age of approximately 8 years.

General thinking in the aging research field is that interventions are likely to affect subsets of the population, and no one intervention (lifestyle or small molecule) will delay or reduce biological age in the entire population. Surprisingly, in this group the vast majority of participants responded with a reduced biological age after Rejuvant® treatment. While the study does have limitations (described below), these findings are encouraging. Interestingly, there were two parameters that influenced the magnitude of the response: those participants with higher biologic age relative to chronological age and those with higher chronological age at baseline. This suggests, perhaps contrary to expectations given the known role of AKG in augmenting exercise performance, that Rejuvant® has a larger response in participants biologically older than their chronological age. One might also predict this outcome for a longevity intervention on the basis of the hypothesis that individuals with low relative biological age are already undergoing near optimized aging and have less to gain. Currently, there is insufficient data on human aging to predict which populations will respond to a particular intervention.

The TruAge methylation test, which remains proprietary, was developed by examining a limited number of methylation sites in CpG islands of promoters, based on optimization to chronological age using a machine learning approach. While it surveys a smaller portion of the genome than other methylation clocks, it has the advantage of being more affordable. In addition, TruAge test is easily used by consumers, who place saliva on a paper card and mail in the sample for analysis. The TruAge test was shown to report similar results when compared to other epigenetic clocks (unpublished), yet further testing using other methylation clocks and different biomarkers of aging would be beneficial to measure the effects of Rejuvant®

on human longevity. A fundamental question regarding different biological aging measures relates to their level of concordance: do they measure the same, overlapping or completely different aspects of the aging process?

The data in this study, while limited, suggests that CaAKG may indeed impact aging, at least as measured by methylation. It is also worth noting that AKG is a known substrate for DNA demethylases [31], which potentially demethylate DNA sites interrogated by TruAge. However, the AKG supplementation leads to both demethylation and hyper methylation of some CpG sites in saliva cells, suggesting that Rejuvant® may have a larger effect on methylation-based aging clocks than other indicators of biologic age.

There are several limitations to this study. Primarily, it is not placebo controlled. Therefore, one potential concern is that the placebo effect may have contributed to some extent to the changes observed. However, the self-reported trust in the efficacy of dietary supplements was not deemed a statistically significant predictor in any of our regression models, which mitigates risk to an extent. Moreover, the study describes a limited sample size and we were unable to collect other kinds of data relevant to aging, for instance clinical markers of aging and disease, and apply other biological aging clocks [6]. Future randomized clinical trials will be required to confirm the findings presented here. Nevertheless, the results in this manuscript suggest that Rejuvant® may have significant effects on biological age as measured by DNA methylation of saliva samples.

MATERIALS AND METHODS

Participants

A group of 42 self-reported healthy individuals (14 females and 28 males) who had submitted saliva samples (two samples per subject). Saliva samples were collected at Baseline (T0) and 4-10 months after the participant began taking Rejuvant® (T7) at a fixed dose of two tablets per day. Each dose contained 1 gram of Calcium Alpha-Ketoglutarate, along with Vitamin A for the male participant's formulation or Vitamin D for the female participant's formulation, and delivered in a timed-release formulation, as illustrated in the formulation labels.

TruMe identified prospective study participants from all customers with two previously completed DNAm tests (one baseline before starting and a second test 4 to 10 months Rejuvant(R) supplementation. Prospective subjects were consented and asked to fill out a questionnaire reporting lifestyle changes before and after supplementation in diet, exercise, sleep, alcohol

consumption, smoking and nutritional supplement use. The consent form included the following statement: "TruMe would like to have your permission to use your biological age results for scientific and academic purposes. You will always be anonymous and no personally identifiable information will ever be shared. TruMe does not use full genome sequencing and therefore does not generate nor maintain any genetically identifiable data. We never sell your data or personal information." Participants who provided appropriate consent following GCP principles, were included in the study. Analysis of participant data was performed in aggregate and anonymously (Table 1).

Vitamin A (as retinyl palmitate)	900 mcg	100%
Calcium	190 mg	15%
Calcium Alpha-Ketoglutarate Monohydrate (LifeAKG™)	1000 mg	†

Vitamin D	25 mcg
Calcium	190 mg
Calcium Alpha-Ketoglutarate Monohydrate (LifeAKG™)	1000 mg

Sample collection and bisulfate sequencing

Saliva samples were self-collected by participants at home using commercially available TruMe sampling kits. Participants were instructed to collect about 200-300 mL of their saliva samples onto FTA Classic Cards (FTA Classic Cards, #WB120205, from GE Healthcare Life Sciences). Saliva samples were allowed to air dry for 30-45 minutes, before they were shipped to TruMe Labs.

DNA methylation and DNAm age calculation

From each sample, 1 inch diameter circles were obtained, and DNA eluted with Quick-DNA Microprep Plus Kit (ZymoResearch, CA, USA) according to the manufacturer's protocol. 200-500ng of eluted DNA was bisulfite converted with the EZ DNA Methylation-Lighting™ Kit according to the manufacturer's instructions (ZymoResearch, CA, USA). PCR amplification of bisulfite converted DNA was performed using standard target specific primers (IDT, Newark, NJ, USA). The PCR reaction was set up using ZymoTaq PreMix E2004 (ZymoResearch, CA, USA).

Each PCR fragment was analyzed using the standard Sanger sequencing protocol and methylation levels were analyzed using a proprietary algorithm, developed by TruMe Inc. The TruMe age-prediction algorithm uses a

multivariate model to predict biological age of the individual.

Statistical analysis

The data was analyzed, and the plots generated using the R programming language. Continuous variables were tested for normality using the Shapiro-Wilk test. In cases, where we fail to reject the null hypothesis (p-value not less than 0.05) the one-sided Welch two sample paired t-test was used, otherwise the one-sided Wilcoxon signed rank paired test with continuity correction was deployed [32]. Figures 1–5 were done using the 'ggpubr' R package. Figure 6 was created using the 'scatterplot3d' R package [33].

AUTHOR CONTRIBUTIONS

O.D. assisted with establishment of the TruMe Age test and was responsible for experiments involving its use. D.B. performed statistical analysis of the data and participated in the composition of the manuscript. V.B. assisted with statistical analysis of the data. R.F. assisted with data quality control and analysis, as well as composition of the manuscript. F.R.P. participated in study design, manuscript composition, and data analysis. B.K.K. participated in study design, manuscript composition and data analysis. Y.V.B. participated in establishment of the TruMe Age test, study design, manuscript composition, and data analysis.

ACKNOWLEDGMENTS

The authors would like to thank members of the Kennedy lab at NUS, as well as employees at TruMe Labs and PDL Health for comments on the manuscript.

CONFLICTS OF INTEREST

In July of 2019, TruMe entered into a non-exclusive customer service agreement for the DNA methylation testing of Ponce de Leon Health customers taking Rejuvant®. Neither TruMe nor Ponce de Leon Health have any cross ownership or other financial interests to report. B.K.K. is a scientific consultant and Board member for Ponce de Leon Health.

FUNDING

Data for the manuscript was acquired from users of the Rejuvant product from Ponce de Leon Health and DNA methylation analysis provided by TruMe Labs. Data was provided to National University of Singapore for statistical analysis, which provided funding support for this component of the project.

REFERENCES

1. Kennedy BK, Berger SL, Brunet A, Campisi J, Cuervo AM, Epel ES, Franceschi C, Lithgow GJ, Morimoto RI, Pessin JE, Rando TA, Richardson A, Schadt EE, et al. Geroscience: linking aging to chronic disease. *Cell*. 2014; 159:709–13.
<https://doi.org/10.1016/j.cell.2014.10.039>
PMID:[25417146](https://pubmed.ncbi.nlm.nih.gov/25417146/)
2. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell*. 2013; 153:1194–217.
<https://doi.org/10.1016/j.cell.2013.05.039>
PMID:[23746838](https://pubmed.ncbi.nlm.nih.gov/23746838/)
3. Kennedy BK, Pennypacker JK. Drugs that modulate aging: the promising yet difficult path ahead. *Transl Res*. 2014; 163:456–65.
<https://doi.org/10.1016/j.trsl.2013.11.007>
PMID:[24316383](https://pubmed.ncbi.nlm.nih.gov/24316383/)
4. Wagner KH, Cameron-Smith D, Wessner B, Franzke B. Biomarkers of Aging: From Function to Molecular Biology. *Nutrients*. 2016; 8:338.
<https://doi.org/10.3390/nu8060338>
PMID:[27271660](https://pubmed.ncbi.nlm.nih.gov/27271660/)
5. Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnon JL, Divers J, Espeland MA, Marcovina S, Pollak MN, Kritchevsky SB, Barzilai N, Kuchel GA. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. *Geroscience*. 2018; 40:419–36.
<https://doi.org/10.1007/s11357-018-0042-y>
PMID:[30151729](https://pubmed.ncbi.nlm.nih.gov/30151729/)
6. Kudryashova KS, Burka K, Kulaga AY, Vorobyeva NS, Kennedy BK. Aging Biomarkers: From Functional Tests to Multi-Omics Approaches. *Proteomics*. 2020; 20:e1900408.
<https://doi.org/10.1002/pmic.201900408>
PMID:[32084299](https://pubmed.ncbi.nlm.nih.gov/32084299/)
7. Cavalli G, Heard E. Advances in epigenetics link genetics to the environment and disease. *Nature*. 2019; 571:489–99.
<https://doi.org/10.1038/s41586-019-1411-0>
PMID:[31341302](https://pubmed.ncbi.nlm.nih.gov/31341302/)
8. Unnikrishnan A, Freeman WM, Jackson J, Wren JD, Porter H, Richardson A. The role of DNA methylation in epigenetics of aging. *Pharmacol Ther*. 2019; 195:172–85.
<https://doi.org/10.1016/j.pharmthera.2018.11.001>
PMID:[30419258](https://pubmed.ncbi.nlm.nih.gov/30419258/)
9. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sada S, Klotzle B, Bibikova M, Fan JB, Gao Y, Deconde R, Chen M, Rajapakse I, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell*. 2013; 49:359–67.
<https://doi.org/10.1016/j.molcel.2012.10.016>
PMID:[23177740](https://pubmed.ncbi.nlm.nih.gov/23177740/)
10. Jin B, Li Y, Robertson KD. DNA methylation: superior or subordinate in the epigenetic hierarchy? *Genes Cancer*. 2011; 2:607–17.
<https://doi.org/10.1177/1947601910393957>
PMID:[21941617](https://pubmed.ncbi.nlm.nih.gov/21941617/)
11. Teschendorff AE, West J, Beck S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? *Hum Mol Genet*. 2013; 22:R7–15.
<https://doi.org/10.1093/hmg/ddt375> PMID:[23918660](https://pubmed.ncbi.nlm.nih.gov/23918660/)
12. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol*. 2013; 14:R115.
<https://doi.org/10.1186/gb-2013-14-10-r115>
PMID:[24138928](https://pubmed.ncbi.nlm.nih.gov/24138928/)
13. Bocklandt S, Lin W, Sehl ME, Sánchez FJ, Sinsheimer JS, Horvath S, Vilain E. Epigenetic predictor of age. *PLoS One*. 2011; 6:e14821.
<https://doi.org/10.1371/journal.pone.0014821>
PMID:[21731603](https://pubmed.ncbi.nlm.nih.gov/21731603/)
14. Breitling LP, Saum KU, Perna L, Schöttker B, Holleczek B, Brenner H. Frailty is associated with the epigenetic clock but not with telomere length in a German cohort. *Clin Epigenetics*. 2016; 8:21.
<https://doi.org/10.1186/s13148-016-0186-5>
PMID:[26925173](https://pubmed.ncbi.nlm.nih.gov/26925173/)
15. Marioni RE, Shah S, McRae AF, Ritchie SJ, Muniz-Terrera G, Harris SE, Gibson J, Redmond P, Cox SR, Pattie A, Corley J, Taylor A, Murphy L, et al. The epigenetic clock is correlated with physical and cognitive fitness in the Lothian Birth Cohort 1936. *Int J Epidemiol*. 2015; 44:1388–96.
<https://doi.org/10.1093/ije/dyv277> PMID:[25617346](https://pubmed.ncbi.nlm.nih.gov/25617346/)
16. Horvath S, Erhart W, Brosch M, Ammerpohl O, von Schönfels W, Ahrens M, Heits N, Bell JT, Tsai PC, Spector TD, Deloukas P, Siebert R, Sipos B, et al. Obesity accelerates epigenetic aging of human liver. *Proc Natl Acad Sci USA*. 2014; 111:15538–43.
<https://doi.org/10.1073/pnas.1412759111>
PMID:[25313081](https://pubmed.ncbi.nlm.nih.gov/25313081/)
17. Horvath S, Garagnani P, Bacalini MG, Pirazzini C, Salvioli S, Gentilini D, Di Blasio AM, Giuliani C, Tung S, Vinters HV, Franceschi C. Accelerated epigenetic aging in Down syndrome. *Aging Cell*. 2015; 14:491–95.
<https://doi.org/10.1111/accel.12325>
PMID:[25678027](https://pubmed.ncbi.nlm.nih.gov/25678027/)
18. Lagathu C, Cossarizza A, Béréziat V, Nasi M, Capeau J, Pinti M. Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers. *AIDS*. 2017 (Suppl 2); 31:S105–19.

- <https://doi.org/10.1097/QAD.0000000000001441>
PMID:[28471941](https://pubmed.ncbi.nlm.nih.gov/28471941/)
19. Horvath S, Ritz BR. Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients. *Aging* (Albany NY). 2015; 7:1130–42.
<https://doi.org/10.18632/aging.100859>
PMID:[26655927](https://pubmed.ncbi.nlm.nih.gov/26655927/)
20. Levine ME, Lu AT, Bennett DA, Horvath S. Epigenetic age of the pre-frontal cortex is associated with neurotic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. *Aging* (Albany NY). 2015; 7:1198–211.
<https://doi.org/10.18632/aging.100864>
PMID:[26684672](https://pubmed.ncbi.nlm.nih.gov/26684672/)
21. Ambatipudi S, Horvath S, Perrier F, Cuenin C, Hernandez-Vargas H, Le Calvez-Kelm F, Durand G, Byrnes G, Ferrari P, Bouaoun L, Sklias A, Chajes V, Overvad K, et al. DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. *Eur J Cancer*. 2017; 75:299–307.
<https://doi.org/10.1016/j.ejca.2017.01.014>
PMID:[28259012](https://pubmed.ncbi.nlm.nih.gov/28259012/)
22. Zannas AS, Arloth J, Carrillo-Roa T, Iurato S, Röh S, Ressler KJ, Nemeroff CB, Smith AK, Bradley B, Heim C, Menke A, Lange JF, Brückl T, et al. Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling. *Genome Biol*. 2015; 16:266.
<https://doi.org/10.1186/s13059-015-0828-5>
PMID:[26673150](https://pubmed.ncbi.nlm.nih.gov/26673150/)
23. Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, Wiley CD, Gan G, Kim DE, Kasler HG, Kuehnemann C, Kaplowitz B, Bhaumik D, et al. Alpha-Ketoglutarate, an Endogenous Metabolite, Extends Lifespan and Compresses Morbidity in Aging Mice. *Cell Metab*. 2020; 32:447–56.e6.
<https://doi.org/10.1016/j.cmet.2020.08.004>
PMID:[32877690](https://pubmed.ncbi.nlm.nih.gov/32877690/)
24. Xiao D, Zeng L, Yao K, Kong X, Wu G, Yin Y. The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications. *Amino Acids*. 2016; 48:2067–80.
<https://doi.org/10.1007/s00726-016-2254-8>
PMID:[27161106](https://pubmed.ncbi.nlm.nih.gov/27161106/)
25. Wu N, Yang M, Gaur U, Xu H, Yao Y, Li D. Alpha-Ketoglutarate: Physiological Functions and Applications. *Biomol Ther* (Seoul). 2016; 24:1–8.
<https://doi.org/10.4062/biomolther.2015.078>
PMID:[26759695](https://pubmed.ncbi.nlm.nih.gov/26759695/)
26. Zdzińska B, Żurek A, Kandefer-Szerszeń M. Alpha-Ketoglutarate as a Molecule with Pleiotropic Activity: Well-Known and Novel Possibilities of Therapeutic Use. *Arch Immunol Ther Exp* (Warsz). 2017; 65:21–36.
<https://doi.org/10.1007/s00005-016-0406-x>
PMID:[27326424](https://pubmed.ncbi.nlm.nih.gov/27326424/)
27. Harrison AP, Pierzynowski SG. Biological effects of 2-oxoglutarate with particular emphasis on the regulation of protein, mineral and lipid absorption/metabolism, muscle performance, kidney function, bone formation and cancerogenesis, all viewed from a healthy ageing perspective state of the art--review article. *J Physiol Pharmacol*. 2008 (Suppl 1); 59:91–106.
PMID:[18802218](https://pubmed.ncbi.nlm.nih.gov/18802218/)
28. Chin RM, Fu X, Pai MY, Vergnes L, Hwang H, Deng G, Diep S, Lomenick B, Meli VS, Monsalve GC, Hu E, Whelan SA, Wang JX, et al. The metabolite α -ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. *Nature*. 2014; 510:397–401.
<https://doi.org/10.1038/nature13264> PMID:[24828042](https://pubmed.ncbi.nlm.nih.gov/24828042/)
29. Liao CY, Kennedy BK. Mouse models and aging: longevity and progeria. *Curr Top Dev Biol*. 2014; 109:249–85.
<https://doi.org/10.1016/B978-0-12-397920-9.00003-2>
PMID:[24947239](https://pubmed.ncbi.nlm.nih.gov/24947239/)
30. Pyrkov TV, Avchaciov K, Tarkhov AE, Menshikov LI, Gudkov AV, Fedichev PO. Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit. *Nat Commun*. 2021; 12:2765.
<https://doi.org/10.1038/s41467-021-23014-1>
PMID:[34035236](https://pubmed.ncbi.nlm.nih.gov/34035236/)
31. Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Krebs cycle intermediates regulate DNA and histone methylation: epigenetic impact on the aging process. *Ageing Res Rev*. 2014; 16:45–65.
<https://doi.org/10.1016/j.arr.2014.05.004>
PMID:[24910305](https://pubmed.ncbi.nlm.nih.gov/24910305/)
32. Runyon NP. *Nonparametric statistics: a contemporary approach*. Addison-Wesley Publishing Company. 1977.
33. Ligges U, Maechler M. *scatterplot3d - An R Package for Visualizing Multivariate Data*. *J Stat Softw*. 2003; 8:1–20.
<https://doi.org/10.18637/jss.v008.i11>

SUPPLEMENTARY MATERIALS

Supplementary Tables

Please browse Full Text version to see the data of Supplementary Table 2.

Supplementary Table 1. Characteristics of participants at baseline.

	Female	Male
n	14	28
Ethnicity (%)		
Asian	1 (7.1)	1 (3.6)
Hispanic/Latino	1 (7.1)	1 (3.6)
White/Caucasian	12 (85.7)	23 (82.1)
White/Caucasian, American Indian or Alaskan Native	0 (0.0)	2 (7.1)
White/Caucasian, Native Hawaiian or other Pacific islander	0 (0.0)	1 (3.6)
Chronological Age T0 (mean (SD))	62.57 (8.11)	61.16 (11.03)
Chronological Age T7* (mean (SD))	63.12 (8.11)	61.76 (11.01)
Biological Age T0 (mean (SD))	61.09 (7.27)	61.38 (9.64)
Biological Age T7* (mean (SD))	54.66 (8.17)	53.53 (8.62)
Weekly alcohol consumption in drinks (%)		
0	5 (35.7)	5 (17.9)
1 to 4	2 (14.3)	10 (35.7)
5 to 8	6 (42.9)	8 (28.6)
9 to 14	1 (7.1)	5 (17.9)
Current number of dietary supplements (%)		
0	2 (14.3)	4 (14.3)
1 to 2	4 (28.6)	3 (10.7)
3 to 4	5 (35.7)	6 (21.4)
5	3 (21.4)	15 (53.6)
Self-rated general health (%)		
Moderate	1 (7.1)	1 (3.6)
Good	7 (50.0)	9 (32.1)
Very good	6 (42.9)	18 (64.3)
Sleep duration (%)		
4-6 hours	1 (7.1)	2 (7.1)
7-8 hours	13 (92.9)	24 (85.7)
More than 8 hours	0 (0.0)	2 (7.1)
Smoking history (%)		
Past smoker but quit	3 (21.4)	3 (10.7)
Never smoker		
Weekly exercise frequency (%)		
Rarely	1 (7.1)	0 (0.0)
1-2 times/week	0 (0.0)	5 (17.9)
3+ times/week	7 (50.0)	17 (60.7)
Daily	6 (42.9)	6 (21.4)
BMI (mean (SD))	21.84 (2.60)	25.70 (3.97)
Days of treatment (mean (SD))	200.57 (35.78)	218.36 (41.57)
Education (%)		
High school diploma (or GED)	1 (7.1)	0 (0.0)
Some college	3 (21.4)	4 (14.3)
4-year college degree	2 (14.3)	10 (35.7)
Graduate-level degree	8 (57.1)	14 (50.0)
Average number of daily meals (%)		
2	6 (42.9)	11 (39.3)

3	7 (50.0)	14 (50.0)
4 or more	1 (7.1)	3 (10.7)
Number of daily snacks (%)		
1	6 (42.9)	18 (64.3)
2	6 (42.9)	8 (28.6)
3	2 (14.3)	2 (7.1)
Opinion about dietary supplements (%)		
Skeptical	2 (14.3)	3 (10.7)
No opinion	2 (14.3)	0 (0.0)
Interested	6 (42.9)	4 (14.3)
Firm believer	4 (28.6)	21 (75.0)
Weekly frequency of dietary supplements (%)		
Never	1 (7.1)	0 (0.0)
Rarely	0 (0.0)	1 (3.6)
Daily	13 (92.9)	27 (96.4)
Healthy living mindset (%)		
Ready to get started	1 (7.1)	1 (3.6)
Practicing	10 (71.4)	15 (53.6)
Dedicated	3 (21.4)	12 (42.9)
Activity level (%)		
Sedentary	1 (7.1)	2 (7.1)
Mildly Active	2 (14.3)	5 (17.9)
Active	5 (35.7)	12 (42.9)
Very Active	6 (42.9)	9 (32.1)
Athletic	0 (0.0)	0 (0.0)
Hair (%)		
Bald	0 (0.0)	4 (14.3)
Thinning	5 (35.7)	11 (39.3)
Thick and/or Full	9 (64.3)	13 (46.4)

*Indicates biologic age as measured by TruMe test after an average of seven months of treatment.

Supplementary Table 2. Regression models used (with coefficients).